Factors affecting the patient’s knowledge, experience andmedication adherence with isotretinoin: A cross sectional studyamong Jordanian patients
Main Article Content
Keywords
knowledge, experience, adherence, isotretinoin, Jordan
Abstract
Aim: This study aims to evaluate the factors affecting the patient’s knowledge, experience and medication adherence with isotretinoin. Methods: This cross-sectional study, conducted in Jordan from October 2023 to February 2024, utilized Google Forms to create a self-administered online survey for data collection. Multiple-linear regression analysis was conducted to study the predictors affecting knowledge, experience (using SKINDEX-16 scale) and adherence of patients to isotretinoin (using LMAS-14 scale). Results: A total of 147 responses were included in the final analysis. The majority of the study participants were females (133, 90.5%), holding bachelor’s degree (126, 85.7%), single (116, 78.9%) and living in urban areas (118, 80.3%). Study participants demonstrated a moderate level of knowledge (mean score was 14.25±3.97 out of 22), a positive experience, and adherent to isotretinoin (mean score was 4.61±2.48). The knowledge score about isotretinoin was positively affected by female gender, university education, living in urban areas, and previous experience with isotretinoin use. While patient experience with isotretinoin was positive, increasing the participant’s age. Regarding medication adherence, it was positively affected by previous experience with isotretinoin and the doctor-patient communication score. Conclusion: These findings emphasize the need for tailored interventions to improve education, communication, and support, ultimately enhancing treatment outcomes and patient satisfaction with isotretinoin therapy. Future research could explore longitudinal trends and additional factors affecting medication adherence in this context.
References
1. K. M. AlGhamdi and S. A. AlShammari, “Arabic version of Skindex-16: translation and cultural adaptation, with assessment of reliability and validity.,” Int J Dermatol, vol. 46, no. 3, pp. 247–52, Mar. 2007, doi: 10.1111/j.1365-4632.2007.03013.x.
2. C. C. Zouboulis and V. Bettoli, “Management of severe acne,” British Journal of Dermatology, vol. 172, pp. 27–36, Jul. 2015, doi: 10.1111/bjd.13639.
3. Y. A. Alfouzan et al., “Isotretinoin-Related Eye Dryness in Acne Patients in Qassim, Saudi Arabia.,” Cureus, vol. 15, no. 12, p. e49904, Dec. 2023, doi: 10.7759/cureus.49904.
4. A. Alamri, R. Khafaji, A. Balkhy, S. Samarkandy, and A. Alraddadi, “The Psychological Impact of Isotretinoin Therapy on Acne Vulgaris Patients.,” Cureus, vol. 15, no. 12, p. e50612, Dec. 2023, doi: 10.7759/cureus.50612.
5. N. Biset et al., “Assessment of medication adherence and responsible use of isotretinoin and contraception through Belgian community pharmacies by using pharmacy refill data,” Patient Prefer Adherence, vol. Volume 12, pp. 153–161, Jan. 2018, doi: 10.2147/PPA.S149355.
6. W. A. Alghamdi, H. S. Alwesaibie, M. A. Albesher, F. K. Alghamdi, and A. A. Albaqshi, “Knowledge, Attitude, and Practice Regarding the Use of Isotretinoin in Saudi Arabia.,” Cureus, vol. 15, no. 12, p. e50516, Dec. 2023, doi: 10.7759/cureus.50516.
7. T. Entezari-Maleki et al., “Evaluation and monitoring of isotretinoin use in Iran.,” Arch Iran Med, vol. 15, no. 7, pp. 409–12, Jul. 2012.
8. Z. M. Alshaalan, “Knowledge on the Use of Isotretinoin and Its Side Effects and Awareness towards Saudi FDA-Pregnancy Prevention Program among the Female Acne Patients: A Northern Saudi Study,” Medicina (B Aires), vol. 58, no. 11, p. 1609, Nov. 2022, doi: 10.3390/medicina58111609.
9. A. M. Malebari, H. T. Bakhsh, R. M. Musairi, J. O. Alghamdi, and A. A. Alhaddad, “An Assessment of the Knowledge of Oral Isotretinoin (Roaccutane) Treatment Among Pharmacy Students in Saudi Arabia.,” Cureus, vol. 15, no. 6, p. e40388, Jun. 2023, doi: 10.7759/cureus.40388.
10. R. Murshidi et al., “A novel predictive method for risk stratification in acne patients receiving isotretinoin: an analysis of laboratory abnormalities and changes in inflammatory parameters.,” J Dermatolog Treat, vol. 35, no. 1, p. 2301435, Dec. 2024, doi: 10.1080/09546634.2023.2301435.
11. A. S. Jarab, S. Al-Azzam, S. Almutairi, and T. L. Mukattash, “Patients’ Knowledge and Information Needs about Isotretinoin Therapy Use in Jordan.,” Int J Clin Pract, vol. 2022, p. 9443884, 2022, doi: 10.1155/2022/9443884.
12. A. A. Alshehri, B. A. Althobaiti, W. Y. Khawagi, and K. D. Murphy, “Awareness of isotretinoin use and safety in Saudi Arabia: A nationwide cross-sectional study.,” Saudi Pharm J, vol. 31, no. 11, p. 101796, Nov. 2023, doi: 10.1016/j.jsps.2023.101796.
13. M. Al Dhafiri et al., “Isotretinoin Use and Liver Enzymes Changes: A Single-Center Study in Saudi Arabia,” Cureus, Dec. 2023, doi: 10.7759/cureus.51263.
14. R. Y. Alabadallah, B. M. Hijazi, S. M. Altawalbeh, M. Oqal, and B. A. Almomani, “Clinical pharmacist role in improving the knowledge and outcomes in patients using isotretinoin: A randomized, controlled study.,” Heliyon, vol. 9, no. 9, p. e20102, Sep. 2023, doi: 10.1016/j.heliyon.2023.e20102.
15. B. Tabachnick and L. Fidell, Using Multivariate Statistics, 6 th. Pearson, 2013.
16. L. Mroueh et al., “Evaluation of medication adherence among Lebanese diabetic patients,” Pharm Pract (Granada), vol. 16, no. 4, p. 1291, Dec. 2018, doi: 10.18549/PharmPract.2018.04.1291.
17. M. Sustersic et al., “A scale assessing doctor-patient communication in a context of acute conditions based on a systematic review,” PLoS One, vol. 13, no. 2, p. e0192306, Feb. 2018, doi: 10.1371/journal.pone.0192306.
18. R. Bou Serhal et al., “A New Lebanese Medication Adherence Scale: Validation in Lebanese Hypertensive Adults,” Int J Hypertens, vol. 2018, pp. 1–7, 2018, doi: 10.1155/2018/3934296.
19. S. Hallit et al., “Medication adherence among Lebanese adult patients with hypothyroidism: Validation of the Lebanese Medication Adherence Scale and correlates,” Clin Epidemiol Glob Health, vol. 9, pp. 196–201, Jan. 2021, doi: 10.1016/j. cegh.2020.08.014.
20. J. J. Leyden, J. Q. Del Rosso, and E. W. Baum, “The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.,” J Clin Aesthet Dermatol, vol. 7, no. 2 Suppl, pp. S3–S21, Feb. 2014.
21. A. Paichitrojjana and A. Paichitrojjana, “Oral Isotretinoin and Its Uses in Dermatology: A Review,” Drug Des Devel Ther, vol. Volume 17, pp. 2573–2591, Aug. 2023, doi: 10.2147/DDDT.S427530.
22. J. D. Bremner, “Isotretinoin and neuropsychiatric side effects: Continued vigilance is needed,” J Affect Disord Rep, vol. 6, p. 100230, Dec. 2021, doi: 10.1016/j.jadr.2021.100230.
23. C.-C. Draghici, R.-G. Miulescu, R.-C. Petca, A. Petca, M. Dumitrașcu, and F. Șandru, “Teratogenic effect of isotretinoin in both fertile females and males (Review),” Exp Ther Med, vol. 21, no. 5, p. 534, Mar. 2021, doi: 10.3892/etm.2021.9966.
24. P. Brzezinski, K. Borowska, A. Chiriac, and J. Smigielski, “Adverse effects of isotretinoin: A large, retrospective review,” Dermatol Ther, vol. 30, no. 4, p. e12483, Jul. 2017, doi: 10.1111/dth.12483. 25. Ö. Kutlu, A. S. Karadağ, and U. Wollina, “Adult acne versus adolescent acne: a narrative review with a focus on epidemiology to treatment,” An Bras Dermatol, vol. 98, no. 1, pp. 75–83, Jan. 2023, doi: 10.1016/j.abd.2022.01.006.
26. C. N. Collier, J. C. Harper, W. C. Cantrell, W. Wang, K. W. Foster, and B. E. Elewski, “The prevalence of acne in adults 20 years and older,” J Am Acad Dermatol, vol. 58, no. 1, pp. 56–59, Jan. 2008, doi: 10.1016/j.jaad.2007.06.045.
27. A. A. M. Ibrahim et al., “Awareness of isotretinoin use and Saudi FDA pregnancy prevention program in Riyadh, Saudi Arabia: A cross-sectional study among female patients,” Saudi Pharmaceutical Journal, vol. 29, no. 6, pp. 527–532, Jun. 2021, doi: 10.1016/j.jsps.2021.04.013.
28. M. Elsaie, “Hormonal treatment of acne vulgaris: an update,” Clin Cosmet Investig Dermatol, vol. Volume 9, pp. 241–248, Sep. 2016, doi: 10.2147/CCID.S114830.
29. Y. E. Aljefri et al., “Cutaneous Manifestations and Hormonal Changes Among Polycystic Ovary Syndrome Patients at a Tertiary Care Center,” Cureus, Dec. 2021, doi: 10.7759/cureus.20593.
30. E. Chlebus and M. Chlebus, “Factors affecting the course and severity of adult acne. Observational cohort study,” Journal of Dermatological Treatment, vol. 28, no. 8, pp. 737–744, Nov. 2017, doi: 10.1080/09546634.2017.1329500.
31. S. Zari and D. Alrahmani, “The association between stress and acne among female medical students in Jeddah, Saudi Arabia,” Clin Cosmet Investig Dermatol, vol. Volume 10, pp. 503–506, Dec. 2017, doi: 10.2147/CCID.S148499.
32. D. Suh, H. Oh, S. J. Lee, H. J. Kim, and H. J. Ryu, “Relationship between acne and the use of cosmetics: Results of a questionnaire study in 539 Korean individuals,” J Cosmet Dermatol, vol. 20, no. 7, pp. 2172–2178, Jul. 2021, doi: 10.1111/jocd.13853.
33. N. S. Younis and N. Y. Al-Harbi, “Public Understanding and Awareness of Isotretinoin Use and Safety in Al Ahsa, Eastern Saudi Arabia,” Ther Innov Regul Sci, vol. 53, no. 5, pp. 618–622, Sep. 2019, doi: 10.1177/2168479018807677.
34. B. Tugrul Ayanoglu, H. G. Demirdag, B. Yalici Armagan, and O. Bezirgan, “Perceptions about oral isotretinoin treatment,” Dermatol Ther, vol. 32, no. 3, May 2019, doi: 10.1111/dth.12873.
35. A. Kara Polat et al., “Knowledge levels and concerns about oral isotretinoin treatment in the parents of adolescent acne patients,” Dermatol Ther, vol. 33, no. 4, Jul. 2020, doi: 10.1111/dth.13669.
36. M. Lelubre et al., “Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non- compliance: Survey among French-speaking health care professionals and patients in Belgium,” Pharmacoepidemiol Drug Saf, vol. 27, no. 6, pp. 668–673, Jun. 2018, doi: 10.1002/pds.4441.
37. S. Khiali, A. Gharekhani, and T. Entezari-Maleki, “Isotretinoin; A review on the Utilization Pattern in Pregnancy,” Adv Pharm Bull, vol. 8, no. 3, pp. 377–382, Aug. 2018, doi: 10.15171/apb.2018.044.
38. R. Al-Mekhlafi, R. E. Attiyah, Y. R. Haddad, and L. A. Salah, “Awareness on Teratogenic Effects of Isotretinoin and Compliance with Precautionary Measures among Women of Childbearing Age in Makkah Province, Saudi Arabia,” Obstet Gynecol Int, vol. 2021, pp. 1–6, Apr. 2021, doi: 10.1155/2021/9966300.
39. M. Al-Harbi, “Concerns and awareness of acne patients about isotretinoin in qassim region of saudi arabia.,” Int J Health Sci (Qassim), vol. 4, no. 1, pp. 47–51, Jan. 2010.
40. A. Sadeghzadeh-Bazargan, M. Ghassemi, A. Goodarzi, M. Roohaninasab, N. Najar Nobari, and E. Behrangi, “Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies,” Dermatol Ther, vol. 34, no. 1, Jan. 2021, doi: 10.1111/dth.14438.
41. M. Imam, R. Abdel-Sattar, G. Aldajani, R. Alsultan, and Y. Aldajani, “Knowledge and awareness of acne patients about isotretinoin use and safety in dawadmi governorate, riyadh region, Saudi Arabia,” Systematic reviews in pharmacy , vol. 12(3), pp. 71–75, 2021.
42. R.-L. Ding, Y. Zheng, and J. Bu, “Physiological and Psychological Effects of Isotretinoin in the Treatment of Patients with Acne: A Narrative Review,” Clin Cosmet Investig Dermatol, vol. Volume 16, pp. 1843–1854, Jul. 2023, doi: 10.2147/CCID.S416267.
43. C. Li, J. Chen, W. Wang, M. Ai, Q. Zhang, and L. Kuang, “Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis,” BMJ Open, vol. 9, no. 1, p. e021549, Jan. 2019, doi: 10.1136/bmjopen-2018-021549.
44. V. Bettoli, A. Guerra-Tapia, M. I. Herane, and J. Piquero Martín, “
45. X. Tan et al., “Medication Adherence, Healthcare Costs and Utilization Associated with Acne Drugs in Medicaid Enrollees with Acne Vulgaris,” Am J Clin Dermatol, vol. 14, no. 3, pp. 243–251, Jun. 2013, doi: 10.1007/s40257-013-0016-x.
46. B. Dréno et al., “Large-scale worldwide observational study of adherence with acne therapy,” Int J Dermatol, vol. 49, no. 4, pp. 448–456, Apr. 2010, doi: 10.1111/j.1365-4632.2010.04416.x.
47. S. S. Zaghloul, W. J. Cunliffe, and M. J. D. Goodfield, “Objective assessment of compliance with treatments in acne,” British Journal of Dermatology, vol. 152, no. 5, pp. 1015–1021, May 2005, doi: 10.1111/j.1365-2133.2005.06357.x.
48. S. Rahrovan, F. Fanian, P. Mehryan, P. Humbert, and A. Firooz, “Male versus female skin: What dermatologists and cosmeticians should know,” Int J Womens Dermatol, vol. 4, no. 3, pp. 122–130, Sep. 2018, doi: 10.1016/j.ijwd.2018.03.002.
49. S. Snyder, I. Crandell, S. A. Davis, and S. R. Feldman, “Medical Adherence to Acne Therapy: A Systematic Review,” Am J Clin Dermatol, vol. 15, no. 2, pp. 87–94, Apr. 2014, doi: 10.1007/s40257-014-0063-y.
50. K. Kvarnström, A. Westerholm, M. Airaksinen, and H. Liira, “Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research,” Pharmaceutics, vol. 13, no. 7, p. 1100, Jul. 2021, doi: 10.3390/ pharmaceutics13071100.
51. E. Lee and M. Choi, “Factors associated with medication adherence among older adults with multimorbidity: A culture perspective,” Geriatr Nurs (Minneap), vol. 55, pp. 297–303, Jan. 2024, doi: 10.1016/j.gerinurse.2023.11.018.
52. A. C. Berman and D. S. Chutka, “Assessing effective physician-patient communication skills: ‘Are you listening to me, doc?,’” Korean J Med Educ, vol. 28, no. 2, pp. 243–249, Jun. 2016, doi: 10.3946/kjme.2016.21.
53. A. King and R. B. Hoppe, “‘Best Practice’ for Patient-Centered Communication: A Narrative Review,” J Grad Med Educ, vol. 5, no. 3, pp. 385–393, Sep. 2013, doi: 10.4300/JGME-D-13-00072.1.
2. C. C. Zouboulis and V. Bettoli, “Management of severe acne,” British Journal of Dermatology, vol. 172, pp. 27–36, Jul. 2015, doi: 10.1111/bjd.13639.
3. Y. A. Alfouzan et al., “Isotretinoin-Related Eye Dryness in Acne Patients in Qassim, Saudi Arabia.,” Cureus, vol. 15, no. 12, p. e49904, Dec. 2023, doi: 10.7759/cureus.49904.
4. A. Alamri, R. Khafaji, A. Balkhy, S. Samarkandy, and A. Alraddadi, “The Psychological Impact of Isotretinoin Therapy on Acne Vulgaris Patients.,” Cureus, vol. 15, no. 12, p. e50612, Dec. 2023, doi: 10.7759/cureus.50612.
5. N. Biset et al., “Assessment of medication adherence and responsible use of isotretinoin and contraception through Belgian community pharmacies by using pharmacy refill data,” Patient Prefer Adherence, vol. Volume 12, pp. 153–161, Jan. 2018, doi: 10.2147/PPA.S149355.
6. W. A. Alghamdi, H. S. Alwesaibie, M. A. Albesher, F. K. Alghamdi, and A. A. Albaqshi, “Knowledge, Attitude, and Practice Regarding the Use of Isotretinoin in Saudi Arabia.,” Cureus, vol. 15, no. 12, p. e50516, Dec. 2023, doi: 10.7759/cureus.50516.
7. T. Entezari-Maleki et al., “Evaluation and monitoring of isotretinoin use in Iran.,” Arch Iran Med, vol. 15, no. 7, pp. 409–12, Jul. 2012.
8. Z. M. Alshaalan, “Knowledge on the Use of Isotretinoin and Its Side Effects and Awareness towards Saudi FDA-Pregnancy Prevention Program among the Female Acne Patients: A Northern Saudi Study,” Medicina (B Aires), vol. 58, no. 11, p. 1609, Nov. 2022, doi: 10.3390/medicina58111609.
9. A. M. Malebari, H. T. Bakhsh, R. M. Musairi, J. O. Alghamdi, and A. A. Alhaddad, “An Assessment of the Knowledge of Oral Isotretinoin (Roaccutane) Treatment Among Pharmacy Students in Saudi Arabia.,” Cureus, vol. 15, no. 6, p. e40388, Jun. 2023, doi: 10.7759/cureus.40388.
10. R. Murshidi et al., “A novel predictive method for risk stratification in acne patients receiving isotretinoin: an analysis of laboratory abnormalities and changes in inflammatory parameters.,” J Dermatolog Treat, vol. 35, no. 1, p. 2301435, Dec. 2024, doi: 10.1080/09546634.2023.2301435.
11. A. S. Jarab, S. Al-Azzam, S. Almutairi, and T. L. Mukattash, “Patients’ Knowledge and Information Needs about Isotretinoin Therapy Use in Jordan.,” Int J Clin Pract, vol. 2022, p. 9443884, 2022, doi: 10.1155/2022/9443884.
12. A. A. Alshehri, B. A. Althobaiti, W. Y. Khawagi, and K. D. Murphy, “Awareness of isotretinoin use and safety in Saudi Arabia: A nationwide cross-sectional study.,” Saudi Pharm J, vol. 31, no. 11, p. 101796, Nov. 2023, doi: 10.1016/j.jsps.2023.101796.
13. M. Al Dhafiri et al., “Isotretinoin Use and Liver Enzymes Changes: A Single-Center Study in Saudi Arabia,” Cureus, Dec. 2023, doi: 10.7759/cureus.51263.
14. R. Y. Alabadallah, B. M. Hijazi, S. M. Altawalbeh, M. Oqal, and B. A. Almomani, “Clinical pharmacist role in improving the knowledge and outcomes in patients using isotretinoin: A randomized, controlled study.,” Heliyon, vol. 9, no. 9, p. e20102, Sep. 2023, doi: 10.1016/j.heliyon.2023.e20102.
15. B. Tabachnick and L. Fidell, Using Multivariate Statistics, 6 th. Pearson, 2013.
16. L. Mroueh et al., “Evaluation of medication adherence among Lebanese diabetic patients,” Pharm Pract (Granada), vol. 16, no. 4, p. 1291, Dec. 2018, doi: 10.18549/PharmPract.2018.04.1291.
17. M. Sustersic et al., “A scale assessing doctor-patient communication in a context of acute conditions based on a systematic review,” PLoS One, vol. 13, no. 2, p. e0192306, Feb. 2018, doi: 10.1371/journal.pone.0192306.
18. R. Bou Serhal et al., “A New Lebanese Medication Adherence Scale: Validation in Lebanese Hypertensive Adults,” Int J Hypertens, vol. 2018, pp. 1–7, 2018, doi: 10.1155/2018/3934296.
19. S. Hallit et al., “Medication adherence among Lebanese adult patients with hypothyroidism: Validation of the Lebanese Medication Adherence Scale and correlates,” Clin Epidemiol Glob Health, vol. 9, pp. 196–201, Jan. 2021, doi: 10.1016/j. cegh.2020.08.014.
20. J. J. Leyden, J. Q. Del Rosso, and E. W. Baum, “The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.,” J Clin Aesthet Dermatol, vol. 7, no. 2 Suppl, pp. S3–S21, Feb. 2014.
21. A. Paichitrojjana and A. Paichitrojjana, “Oral Isotretinoin and Its Uses in Dermatology: A Review,” Drug Des Devel Ther, vol. Volume 17, pp. 2573–2591, Aug. 2023, doi: 10.2147/DDDT.S427530.
22. J. D. Bremner, “Isotretinoin and neuropsychiatric side effects: Continued vigilance is needed,” J Affect Disord Rep, vol. 6, p. 100230, Dec. 2021, doi: 10.1016/j.jadr.2021.100230.
23. C.-C. Draghici, R.-G. Miulescu, R.-C. Petca, A. Petca, M. Dumitrașcu, and F. Șandru, “Teratogenic effect of isotretinoin in both fertile females and males (Review),” Exp Ther Med, vol. 21, no. 5, p. 534, Mar. 2021, doi: 10.3892/etm.2021.9966.
24. P. Brzezinski, K. Borowska, A. Chiriac, and J. Smigielski, “Adverse effects of isotretinoin: A large, retrospective review,” Dermatol Ther, vol. 30, no. 4, p. e12483, Jul. 2017, doi: 10.1111/dth.12483. 25. Ö. Kutlu, A. S. Karadağ, and U. Wollina, “Adult acne versus adolescent acne: a narrative review with a focus on epidemiology to treatment,” An Bras Dermatol, vol. 98, no. 1, pp. 75–83, Jan. 2023, doi: 10.1016/j.abd.2022.01.006.
26. C. N. Collier, J. C. Harper, W. C. Cantrell, W. Wang, K. W. Foster, and B. E. Elewski, “The prevalence of acne in adults 20 years and older,” J Am Acad Dermatol, vol. 58, no. 1, pp. 56–59, Jan. 2008, doi: 10.1016/j.jaad.2007.06.045.
27. A. A. M. Ibrahim et al., “Awareness of isotretinoin use and Saudi FDA pregnancy prevention program in Riyadh, Saudi Arabia: A cross-sectional study among female patients,” Saudi Pharmaceutical Journal, vol. 29, no. 6, pp. 527–532, Jun. 2021, doi: 10.1016/j.jsps.2021.04.013.
28. M. Elsaie, “Hormonal treatment of acne vulgaris: an update,” Clin Cosmet Investig Dermatol, vol. Volume 9, pp. 241–248, Sep. 2016, doi: 10.2147/CCID.S114830.
29. Y. E. Aljefri et al., “Cutaneous Manifestations and Hormonal Changes Among Polycystic Ovary Syndrome Patients at a Tertiary Care Center,” Cureus, Dec. 2021, doi: 10.7759/cureus.20593.
30. E. Chlebus and M. Chlebus, “Factors affecting the course and severity of adult acne. Observational cohort study,” Journal of Dermatological Treatment, vol. 28, no. 8, pp. 737–744, Nov. 2017, doi: 10.1080/09546634.2017.1329500.
31. S. Zari and D. Alrahmani, “The association between stress and acne among female medical students in Jeddah, Saudi Arabia,” Clin Cosmet Investig Dermatol, vol. Volume 10, pp. 503–506, Dec. 2017, doi: 10.2147/CCID.S148499.
32. D. Suh, H. Oh, S. J. Lee, H. J. Kim, and H. J. Ryu, “Relationship between acne and the use of cosmetics: Results of a questionnaire study in 539 Korean individuals,” J Cosmet Dermatol, vol. 20, no. 7, pp. 2172–2178, Jul. 2021, doi: 10.1111/jocd.13853.
33. N. S. Younis and N. Y. Al-Harbi, “Public Understanding and Awareness of Isotretinoin Use and Safety in Al Ahsa, Eastern Saudi Arabia,” Ther Innov Regul Sci, vol. 53, no. 5, pp. 618–622, Sep. 2019, doi: 10.1177/2168479018807677.
34. B. Tugrul Ayanoglu, H. G. Demirdag, B. Yalici Armagan, and O. Bezirgan, “Perceptions about oral isotretinoin treatment,” Dermatol Ther, vol. 32, no. 3, May 2019, doi: 10.1111/dth.12873.
35. A. Kara Polat et al., “Knowledge levels and concerns about oral isotretinoin treatment in the parents of adolescent acne patients,” Dermatol Ther, vol. 33, no. 4, Jul. 2020, doi: 10.1111/dth.13669.
36. M. Lelubre et al., “Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non- compliance: Survey among French-speaking health care professionals and patients in Belgium,” Pharmacoepidemiol Drug Saf, vol. 27, no. 6, pp. 668–673, Jun. 2018, doi: 10.1002/pds.4441.
37. S. Khiali, A. Gharekhani, and T. Entezari-Maleki, “Isotretinoin; A review on the Utilization Pattern in Pregnancy,” Adv Pharm Bull, vol. 8, no. 3, pp. 377–382, Aug. 2018, doi: 10.15171/apb.2018.044.
38. R. Al-Mekhlafi, R. E. Attiyah, Y. R. Haddad, and L. A. Salah, “Awareness on Teratogenic Effects of Isotretinoin and Compliance with Precautionary Measures among Women of Childbearing Age in Makkah Province, Saudi Arabia,” Obstet Gynecol Int, vol. 2021, pp. 1–6, Apr. 2021, doi: 10.1155/2021/9966300.
39. M. Al-Harbi, “Concerns and awareness of acne patients about isotretinoin in qassim region of saudi arabia.,” Int J Health Sci (Qassim), vol. 4, no. 1, pp. 47–51, Jan. 2010.
40. A. Sadeghzadeh-Bazargan, M. Ghassemi, A. Goodarzi, M. Roohaninasab, N. Najar Nobari, and E. Behrangi, “Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies,” Dermatol Ther, vol. 34, no. 1, Jan. 2021, doi: 10.1111/dth.14438.
41. M. Imam, R. Abdel-Sattar, G. Aldajani, R. Alsultan, and Y. Aldajani, “Knowledge and awareness of acne patients about isotretinoin use and safety in dawadmi governorate, riyadh region, Saudi Arabia,” Systematic reviews in pharmacy , vol. 12(3), pp. 71–75, 2021.
42. R.-L. Ding, Y. Zheng, and J. Bu, “Physiological and Psychological Effects of Isotretinoin in the Treatment of Patients with Acne: A Narrative Review,” Clin Cosmet Investig Dermatol, vol. Volume 16, pp. 1843–1854, Jul. 2023, doi: 10.2147/CCID.S416267.
43. C. Li, J. Chen, W. Wang, M. Ai, Q. Zhang, and L. Kuang, “Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis,” BMJ Open, vol. 9, no. 1, p. e021549, Jan. 2019, doi: 10.1136/bmjopen-2018-021549.
44. V. Bettoli, A. Guerra-Tapia, M. I. Herane, and J. Piquero Martín, “
Challenges and Solutions in Oral Isotretinoin in Acne: Reflections on 35 Years of Experience
,” Clin Cosmet Investig Dermatol, vol. Volume 12, pp. 943–951, Dec. 2019, doi: 10.2147/CCID.S234231.45. X. Tan et al., “Medication Adherence, Healthcare Costs and Utilization Associated with Acne Drugs in Medicaid Enrollees with Acne Vulgaris,” Am J Clin Dermatol, vol. 14, no. 3, pp. 243–251, Jun. 2013, doi: 10.1007/s40257-013-0016-x.
46. B. Dréno et al., “Large-scale worldwide observational study of adherence with acne therapy,” Int J Dermatol, vol. 49, no. 4, pp. 448–456, Apr. 2010, doi: 10.1111/j.1365-4632.2010.04416.x.
47. S. S. Zaghloul, W. J. Cunliffe, and M. J. D. Goodfield, “Objective assessment of compliance with treatments in acne,” British Journal of Dermatology, vol. 152, no. 5, pp. 1015–1021, May 2005, doi: 10.1111/j.1365-2133.2005.06357.x.
48. S. Rahrovan, F. Fanian, P. Mehryan, P. Humbert, and A. Firooz, “Male versus female skin: What dermatologists and cosmeticians should know,” Int J Womens Dermatol, vol. 4, no. 3, pp. 122–130, Sep. 2018, doi: 10.1016/j.ijwd.2018.03.002.
49. S. Snyder, I. Crandell, S. A. Davis, and S. R. Feldman, “Medical Adherence to Acne Therapy: A Systematic Review,” Am J Clin Dermatol, vol. 15, no. 2, pp. 87–94, Apr. 2014, doi: 10.1007/s40257-014-0063-y.
50. K. Kvarnström, A. Westerholm, M. Airaksinen, and H. Liira, “Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research,” Pharmaceutics, vol. 13, no. 7, p. 1100, Jul. 2021, doi: 10.3390/ pharmaceutics13071100.
51. E. Lee and M. Choi, “Factors associated with medication adherence among older adults with multimorbidity: A culture perspective,” Geriatr Nurs (Minneap), vol. 55, pp. 297–303, Jan. 2024, doi: 10.1016/j.gerinurse.2023.11.018.
52. A. C. Berman and D. S. Chutka, “Assessing effective physician-patient communication skills: ‘Are you listening to me, doc?,’” Korean J Med Educ, vol. 28, no. 2, pp. 243–249, Jun. 2016, doi: 10.3946/kjme.2016.21.
53. A. King and R. B. Hoppe, “‘Best Practice’ for Patient-Centered Communication: A Narrative Review,” J Grad Med Educ, vol. 5, no. 3, pp. 385–393, Sep. 2013, doi: 10.4300/JGME-D-13-00072.1.
Article Sidebar
Published
Jun 20, 2026
Article Details
How to Cite
1.
Factors affecting the patient’s knowledge, experience andmedication adherence with isotretinoin: A cross sectional studyamong Jordanian patients. Pharm Pract (Granada) [Internet]. 2026 Jun. 20 [cited 2026 Jun. 21];24(2):1-12. Available from: https://www.pharmacypractice.org/index.php/pp/article/view/3388
Section
Original Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
1.
Factors affecting the patient’s knowledge, experience andmedication adherence with isotretinoin: A cross sectional studyamong Jordanian patients. Pharm Pract (Granada) [Internet]. 2026 Jun. 20 [cited 2026 Jun. 21];24(2):1-12. Available from: https://www.pharmacypractice.org/index.php/pp/article/view/3388